Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37634102)
Watch
English
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
scientific article published on 21 December 2016
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
title
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
author
Brent O'Carrigan
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
Stephen P Jackson
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
author name string
Jessica S Brown
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
Timothy A Yap
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
publication date
21 December 2016
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
published in
Cancer Discovery
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
volume
7
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
issue
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
page(s)
20-37
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
cites work
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Linking DNA Damage and Hormone Signaling Pathways in Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
ATM and ATR Signaling Regulate the Recruitment of Human Telomerase to Telomeres
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Repair Pathway Choices and Consequences at the Double-Strand Break
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Replication stress and cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Ubiquitylation, neddylation and the DNA damage response
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Beyond DNA repair: DNA-PK function in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
New and emerging HDAC inhibitors for cancer treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Wee1 kinase as a target for cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
DNA double strand break repair via non-homologous end-joining
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Regulation of DNA damage responses by ubiquitin and SUMO.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Mammalian base excision repair: the forgotten archangel
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Dual roles of PARP-1 promote cancer growth and progression
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Balancing repair and tolerance of DNA damage caused by alkylating agents
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
DNA interstrand crosslink repair and cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Hallmarks of Cancer: The Next Generation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
The DNA Damage Response: Making It Safe to Play with Knives
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
The DNA-damage response in human biology and disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
The multifaceted mismatch-repair system
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
An exonucleolytic activity of human apurinic/apyrimidinic endonuclease on 3' mispaired DNA
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Megabase chromatin domains involved in DNA double-strand breaks in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
23 August 2017
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
BRCAness revisited
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
An update on PARP inhibitors--moving to the adjuvant setting
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
DNA single-strand break repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
DNA damage and innate immunity: links and trade-offs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Mechanisms underlying mutational signatures in human cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Double strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
One ring to bring them all--the role of Ku in mammalian non-homologous end joining
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Alternative end-joining pathway(s): bricolage at DNA breaks
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
DNA damage sensing by the ATM and ATR kinases.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Deubiquitylating enzymes and DNA damage response pathways
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Targeting ATR in DNA damage response and cancer therapeutics.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Competition, collaboration and coordination--determining how cells bypass DNA damage.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Ubiquitin and SUMO in DNA repair at a glance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Anticancer therapy with checkpoint inhibitors: what, where and when?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
6 September 2017
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
14 September 2017
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
14 September 2017
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
14 September 2017
Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
14 September 2017
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
28 September 2017
PARP inhibitors: the race is on.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
The genetic defect in ataxia-telangiectasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
25 June 2018
DNA REPAIR. Drugging DNA repair.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
WEE1 Kinase As a Target for Cancer Therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Polycomb repressive complex 2 contributes to DNA double-strand break repair
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
HERC2 is an E3 ligase that targets BRCA1 for degradation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Envisioning the future of early anticancer drug development.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
1 September 2018
Shelterin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5300099
retrieved
3 December 2018
A new approach to the study of the base-excision repair pathway using methoxyamine
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/28003236
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/28003236
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/2159-8290.CD-16-0860
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
PMC publication ID
5300099
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
PubMed publication ID
28003236
1 reference
stated in
Europe PubMed Central
PMC publication ID
5300099
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28003236%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 April 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
